Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors

Keyphrases

• Solid Tumors 100%
• Immune Checkpoint 100%
• Checkpoint Immunotherapy 100%
• Emerging Biomarkers 100%
• Cancer Patients 66%
• Tumor Subtype 66%
• Checkpoint Inhibitors 66%
• Tissue Biomarkers 66%
• Breast Cancer 33%
• Chemotherapy 33%
• Tumor 33%
• Programmed Death-ligand 1 (PD-L1) 33%
• Lung 33%
• FDA-approved Drugs 33%
• Survival Benefit 33%
• Melanoma 33%
• Metastatic Disease 33%
• Head-and-neck Cancer 33%
• Immunotherapeutics 33%
• DNA Damage Response 33%
• DNA Damage Response Pathway 33%
• Long-term Survival 33%
• Pembrolizumab 33%
• Clinical Development 33%
• Toxicity Profile 33%
• Bladder Cancer 33%
• Tumor mutation Burden 33%
• Response to Immunotherapy 33%
• Promising Biomarkers 33%
• Durable Response 33%
• Mismatch Repair 33%
• Renal Cancer 33%
• Fatal Toxicity 33%
• Agent-relative 33%
• Liquid Biomarkers 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Biological Marker 100%
• Solid Malignant Neoplasm 100%
• Immunotherapy 100%
• Neoplasm 57%
• Immunotherapy Drug 28%
• Malignant Neoplasm 28%
• Chemotherapy 14%
• Breast Cancer 14%
• Side Effect 14%
• Melanoma 14%
• Immunomodulating Agent 14%
• Pembrolizumab 14%
• Bladder Cancer 14%
• Long Term Survival 14%
• Head and Neck Cancer 14%
• Kidney Cancer 14%

Immunology and Microbiology

• Immunotherapy 100%
• DNA Damage Response 33%
• Immunomodulating Drugs 16%
• Mismatch Repair 16%
• Pembrolizumab 16%
• Programmed Death-Ligand 1 16%
• Neck 16%
• Long Term Survival 16%